Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | CASP4 | P49662 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP9 | P55211 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ESPL1 | Q14674 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2144620 | 0.84 | CASP1 (0.49) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL26621531 | 0.78 | L3MBTL1 (0.37) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL9590694 | 0.76 | CASP1 (0.54) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL15543815 | 0.75 | CASP1 (0.53) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL5474246 | 0.73 | CASP3 (0.54) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL15544539 | 0.73 | CASP1 (0.50) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL31419414 | 0.73 | CASP1 (0.50) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL3592128 | 0.73 | CASP1 (0.50) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL1654900 | 0.72 | PDE3B (0.48) | CASP1CASP3CASP4CASP7CASP9 | |
| SCHEMBL2488932 | 0.72 | LMNA (0.54) | CASP1CASP3CASP4CASP7CASP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1632477-B1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2017-03-01 | — | — | EP | disclosed |
| EP-1632477-B1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-7855198-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855198-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-7855198-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585878-B2 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20070167444-A1 | Benzamide derivative or salt thereof | ASTELLAS PHARMA INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1632477-A1 | BENZAMIDE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270365-A1 | such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics | TRPV1, TRPV2, TRPV3 | CASP1 518/4885CASP3 2461/4885CASP4 1554/4885 |
| US-20070167444-A1 | Benzamide derivative or salt thereof | TRPV1, BDKRB1, BDKRB2 | CASP1 561/4885CASP3 3226/4885CASP4 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.